Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash from Investing Activities (2016 - 2025)

Ultragenyx Pharmaceutical has reported Cash from Investing Activities over the past 10 years, most recently at -$72.2 million for Q4 2025.

  • Quarterly Cash from Investing Activities fell 170.48% to -$72.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $236.0 million through Dec 2025, up 1411.11% year-over-year, with the annual reading at $236.0 million for FY2025, 1411.11% up from the prior year.
  • Cash from Investing Activities was -$72.2 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $117.2 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $119.9 million in Q1 2025 and troughed at -$275.5 million in Q3 2024.
  • The 5-year median for Cash from Investing Activities is $62.4 million (2023), against an average of -$5.1 million.
  • Year-over-year, Cash from Investing Activities soared 397.91% in 2023 and then crashed 528.5% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at $69.1 million in 2021, then crashed by 348.49% to -$171.6 million in 2022, then skyrocketed by 37.64% to -$107.0 million in 2023, then skyrocketed by 195.78% to $102.5 million in 2024, then tumbled by 170.48% to -$72.2 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Cash from Investing Activities are -$72.2 million (Q4 2025), $117.2 million (Q3 2025), and $71.2 million (Q2 2025).